Advertisement
Entire Site
Articles/Fact Sheets
Ask the Experts
Conference Coverage
HIV/AIDS Basics & Prevention
HIV/AIDS Basics & Prevention
Basics & Prevention: Home
HIV/AIDS Basics
HIV Prevention
HIV Testing
Who Gets HIV/AIDS?
Myths About HIV/AIDS
More ...
Just Diagnosed
Just Diagnosed
Just Diagnosed: Home
Choosing a Physician
Coping
HIV Hotlines & Orgs
Telling Others
More ...
HIV Treatment
HIV Treatment
HIV Treatment: Home
Drug Resistance
HIV Medications
Side Effects & Health Problems
Starting Treatment
Women & Pregnancy
More ...
Living With HIV
Living With HIV
Living With HIV: Home
Arts & Entertainment
Beyond Medications
Inspiring Stories
Mental Health
More ...
AIDS Policy & Activism
AIDS Policy & Activism
HIV Policy & Activism: Home
Activist Central
Medicine Recycling
U.S.-Specific News
Developing World News
More ...
HIV Around the World
HIV Around the World
HIV Around the World: Home
Africa
Asia
Latin America
U.S. and Canada
Western Europe
More ...
Conference Coverage
Conference Coverage
Conference Coverage: Home
IDSA 2007
ICAAC 2007
Previous Conferences
Upcoming Conferences
More ...
Seattle Treatment Education Project
STEP Perspective
Table of Contents, Spring 2000
Updates
Pancreatitis Warning
Twice-daily Nelfinavir
What You Should Know About Mixing Cocktails
By Jane Woodward, Pharm.D.
New Hope: AIDS Malignancy Consortium Offers New Hope to People with AIDS-Related Cancer
Interview with Dr. David Aboulafia
Conference Review: 7th Conference on Retroviruses and Opportunistic Infections
By Jeffrey T. Schouten, M.D.; Richard March; and Brian Coppedge
HIV Transmission Risks and Public Health Implications
Viral Load and Risk of Heterosexual Transmission
Primary HIV Infections Associated with Oral Transmission
Final Results from the San Francisco Post-exposure Prevention (PEP) Project
HIV-1 Reinfection: A Documented Case?
Lipodystrophy: More Questions than Answers
Adherence, Adherence
The Latest on Structured Treatment Interruption
Phenotypic Resistance
Reservoirs
Does Drug-resistant HIV Reseed the Latent Resting Pool?
Where Does the Virus Come Back From when HAART is Stopped?
Interleukin-2 May Not Add Much
A New Class of Drugs: Entry Inhibitors
Current FDA-Approved Drugs
Ritonavir Intensification in Indinavir Recipients
Investigational Drugs
ABT-378/Ritonavir in PI-experienced Patients
ABT-378/Ritonavir in Antiretroviral-naive Patients
FTC Plus ddI Plus Efavirenz in Treatment-naive Patients
More on Lipodystrophy: The "Mitochondria" Connection
By Richard March, STEP treatment specialist
A New Type of Anti-HIV Drugs: Fusion Inhibitors
By Ann C. Collier, M.D.
Ask Dr. Jeff
By Dr. Jeff Schouten
This article was provided by
Seattle Treatment Education Project
.
It is a part of the publication
STEP Perspective
.
Advertisement